ClearOnc for Benefits Brokers

The fastest-growing line on your clients' plans, and the tool that wins you the renewal.

Cancer is now the line item that breaks self-funded renewals. ClearOnc gives you a Moffitt-powered way to show any client their exposure, and a solution to bring them, at no cost to you.

Why your clients are listening right now
Cancer is 23.9% of plan spend, the fastest-growing line, and 88% of employers are actively evaluating new health vendors.
23.9%
of employer plan spend is cancer, and rising 7 to 9% a year.
$4.3M
highest single cancer claim in 2024. On a self-funded plan, it lands on the client.
$875K
what a 1% improvement is worth on a 5,000-employee plan.
88%
of employers are actively evaluating new health and wellness vendors.

One conversation your clients aren't having

Most benefits teams can't see the oncology line until a catastrophic claim lands at renewal. The broker who brings it up first, with a real number and a credible answer, is the broker who keeps the account and wins the next one.

ClearOnc is that answer. Moffitt-powered oncology navigation that routes members to the right diagnosis, the right site of care, and the right specialty-drug pathway, before the cost compounds. For you, it's a renewal differentiator you can bring to every self-funded client in your book.

Two tools you can use this week, free

Free to use

Oncology Exposure Calculator

Show any client their own oncology exposure and what a 1% improvement is worth to them. Pre-fills by company so you can walk in with their number.

Open the calculator →
Free to use

Cancer Blind-Spot Scorecard

Six questions, two minutes. Score a client's plan against the gaps that inflate the oncology line, and get a branded readout to bring to the renewal.

Run the scorecard →
When they're ready

The ClearOnc solution

When a client asks "so what do we do about it," you bring ClearOnc: Moffitt-powered navigation that closes the gaps the tools surface, at no cost to you.

Talk to ClearOnc →

Why brokers bring ClearOnc to their book

The whole point: it makes you a better broker to your self-funded clients, for free.

No cost to youClearOnc is a point solution you add to a client's stack, not something you pay for. The tools are free to use across your whole book.
You look proactive at renewalWalk in with a board-ready number on the fastest-growing line on the plan, before a $4M claim forces the conversation.
It makes the relationship stickyThe broker who brought the cancer-cost solution is the one who's hard to replace next cycle.
Moffitt-level credibilityBuilt on the expertise of Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center, so your recommendation carries weight.

Where the 1% hides

The gaps that quietly inflate the oncology line in self-funded plans, each one something ClearOnc closes.

8%
of lung-cancer patients get full NCCN biomarker testing, so plans fund therapies that can't work.
11 of 20
costliest injectable drugs treat cancer, specialty-drug routing is where dollars leak.
1 in 3
cancer patients ever get a survivorship care plan, driving avoidable recurrence cost.
7 to 9%
annual cost growth, a 13-year high, with no matching outcome gain.

Moffitt-powered. ClearOnc is built on the expertise of Moffitt Cancer Center, one of the nation's leading NCI-designated Comprehensive Cancer Centers. Your clients' members get expert-level oncology review without leaving their plan.

20 minutes, broker to broker

We'll show you how brokers are putting ClearOnc in front of self-funded clients, and hand you the tools to run across your book.

Book time with Mike LaVance → Try the scorecard first